



# FINANCIAL TEAR SHEET


## Corporate Profile

Jounce Therapeutics is a clinical stage immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more long-lasting responses to treatment.

## Stock Information

JNCE (COMMON STOCK)	
Exchange	NASDAQ GS (US Dollar)
Price	\$14.97
Change (%)	▲ 0.20 (1.35%)
Volume	91,477
52 Week Low	\$11.05
Market Cap	\$481,947,369
Rolling EPS	0.00
PE Ratio	6775.23
Shares Outstanding	32,194,213

Data as of 09/22/17 4:00 p.m. ET



## Recent Headlines & Events

08/30/17 - 8:01 a.m.

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

08/15/17 - 8:00 a.m.

Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development

08/09/17 - 6:30 a.m.

Jounce Therapeutics Reports Second Quarter 2017 Financial Results

There are currently no events scheduled.

## SEC Filings

FILING DATE	FORM
08/09/17	10-Q
08/09/17	8-K
05/23/17	8-K
05/09/17	10-Q

Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.